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Objective. Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a
KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer
risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively
small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome asso-
ciated with rs61764370.
Methods. Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian
Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association
Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and
BRCA2 (14,765 BRCA1 and 7904 BRCA2mutation carriers).
Results.We foundno associationwith risk of ovarian cancer (OR=0.99, 95% CI 0.94–1.04, p=0.74) or breast
cancer (OR = 0.98, 95% CI 0.94–1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1,
ovarian cancer HR = 1.09, 95% CI 0.97–1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97–1.12, p = 0.27;
BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71–1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94–1.19, p =
0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR =
0.94, 95% CI 0.83–1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87–1.06, p = 0.38), and all other
previously-reported associations.
Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for
patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or
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MicroRNAs (miRNAs) are a class of small non-coding RNAmolecules
that negatively regulate gene expression by binding partially comple-
mentary sites in the 3′ untranslated regions (UTRs) of their target
mRNAs. In this way, miRNAs control many cancer-related biological
pathways involved in cell proliferation, differentiation, and apoptosis
[1]. To date, several inherited variants in microRNAs or miRNA target
sites have been reported to confer increased cancer risks [2]. One such
variant is located in the 3′ UTR of the KRAS gene (rs61764370 T N G)
for which the rarer G allele has been reported to confer an increased
risk of ovarian, breast, and lung cancer [3–7] as well as endometriosis
[8], although not consistently [9–11].
For ovarian cancer, the rs61764370 G allele was also reported to be
associated with increased risk (320 cases, 328 controls). Further in-
creased risks were observed among 23 BRCA1 mutation carriers and
31 women with familial ovarian cancer, but without BRCA1 or BRCA2
mutations [3]. In contrast, no association with ovarian cancer risk was
seen in another, much larger study, based on 8669 cases, 10,012 con-
trols, and 2682 BRCA1mutation carriers [9]. One criticism on the latter
study was that some of the genotype data were for rs17388148, an
imputed proxy for rs61764370; even though rs17388148 is highlycorrelatedwith rs61764370 (r2= 0.97) andwas imputed with high ac-
curacy (r2=0.977) [12,13]. Theminor allele of rs61764370was also as-
sociated with shorter survival time in a study of 279 ovarian cancer
patients diagnosed after age 52 years with platinum-resistant disease
(28 resistant, 263 not resistant) and with sub-optimal debulking sur-
gery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal)
[14]. However, another study observed no association between
rs61764370 and ovarian cancer outcome (329 cases) [15].
For breast cancer, a borderline significant increased frequency of the
rs61764370 G allele was observed in 268 BRCA1mutation carriers with
breast cancer, but not in 127 estrogen receptor (ER)-negative familial
non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent
study, the variant was reported to be associated with increased risk of
ER/PR negative disease (80 cases, 470 controls), as well as with triple
negative breast cancer diagnosedbefore age 52 (111 cases, 250 controls),
regardless of BRCA1mutation status [6]. The validity of these findings has
been questioned given the very small sample sizes and the number of
subgroups tested [16,17]. Another report found no association with spo-
radic or familial breast cancer risk (695 combined cases, 270 controls),
but found that the variant was associated with ERBB2-positive and
high grade disease, based on 153 cases who used post-menopausal hor-
mone replacement therapy [18].
392 A. Hollestelle et al. / Gynecologic Oncology 141 (2016) 386–401It has also been reported, based on 232 women with both primary
ovarian and breast cancer, that the frequency of the G allele at
rs61764370 was increased for those who were screened negative for
BRCA1 and BRCA2 (92 cases), particularly among those enrolled within
two years of their ovarian cancer diagnosis (to minimize survival bias,
30 cases), those diagnosed with post-menopausal ovarian cancer (63
cases), those with a family history of ovarian or breast cancer (24
cases), and those with a third primary cancer (16 cases) [4].
This notable lack of consistency in findings between studiesmight be
expected when appropriate levels of statistical significance are not used
to declare positive findings from multiple small subgroup comparisons
or post-hoc hypotheses [19]. In this respect, the dangers of subgroup
analyses in the context of clinical trials are well-recognized [20]. These
are important caveats, particularly since a genetic test for rs61764370
is currently marketed in the US for risk prediction testing to women
who are at increased risk for developing ovarian and/or breast cancer
orwomenwhohave been diagnosedwith either ovarian or breast cancer
themselves [21]. In general, much larger studies, with sufficient power toTable 1
Associations between KRAS rs61764370 and risk of ovarian and breast cancer.
For BRCA1 and BRCA2mutation carrier analyses, cases are affected BRCA1/BRCA2mutation carri
mated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian
components; breast cancer analyses used BCAC data adjusted for study, age, and the seven Euro
with age as follow-up time and stratified for country; 95% CI, 95% confidence interval.
Number
Cases Controls
Ovarian cancer
All invasive 15,357 30,816
Histology
High-grade serous 6938 30,816
Endometrioid 2151 30,816
Clear cell 1015 30,816
Mucinous 1000 30,816
Low-grade serous 485 30,816
First-degree family history
Ovarian cancer 483 342
Breast or ovarian cancer 477 18,442
BRCA1/2mutation negative 346 15,492
BRCA1mutation carriers 2332 12,433
BRCA2mutation carriers 599 7305
Enrolled within two years of diagnosis
All invasive 10,121 30,815
BRCA1mutation carriers 1095 10,802
BRCA2mutation carriers 270 6509
Menopausal status
Pre- or peri-menopausal 4264 8789
Post-menopausal 11,058 15,903
Prior breast cancer
Enrolled within two years of diagnosis 426 30,815
Post-menopausal ovarian cancer 341 15,903
First degree breast or ovarian cancer family history 202 30,815
Breast cancer
All invasive 33,530 37,640
Receptor status
ER−/PR− 4009 37,043
ER−/PR−/ERBB2− 1673 28,480
First-degree family history
Breast cancer 4357 1943
Ovarian or breast cancer 4593 2265
Age diagnosis b52
ER−/PR− 1530 37,043
ER−/PR−/ERBB2− 546 27,690
BRCA1/2mutation negative 1431 1097
BRCA1mutation carriers 7543 7222
BRCA2mutation carriers 4138 3766
Enrolled within two years of diagnosis
All invasive 20,444 34,349
BRCA1mutation carriers 2595 5976
BRCA2mutation carriers 1359 3365
Menopausal status
Pre- or peri-menopausal 7086 8642
Post-menopausal 16,346 18,605detect positivefindings atmuchmore stringent levels of statistical signif-
icance ought to be required to establish the clinical validity of a genetic
test. Therefore, we conducted centralized genotyping of rs61764370
and other variants in the genomic region around the KRAS gene in
140,012 women to examine associations with risk and clinical outcome
of ovarian and breast cancer.
2. Methods
2.1. Study participants
The following three consortia contributed to these analyses: the
Ovarian Cancer Association Consortium (OCAC: 41 studies, Supplemen-
tary Table S1) [22], the Breast Cancer Association Consortium (BCAC: 37
studies, Supplementary Table S2) [23], and the Consortium ofModifiers
of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3)
[24,25]. OCAC and BCAC consisted of case–control studies of unrelated
women, and CIMBA consisted of studies of women with germlineers and controls are unaffected BRCA1/BRCA2mutation carriers, and relative risks are esti-
cancer analyses used OCAC data adjusted for study, age, and the five European principal
pean principal components; BRCA1 and BRCA2mutation carrier analyses used CIMBA data
Minor allele frequency Relative risk (95% CI)
Cases Controls p-Value
0.0914 0.0949 0.99 (0.94–1.04) 0.74
0.0946 0.0949 1.04 (0.97–1.11) 0.26
0.0834 0.0949 0.90 (0.80–1.00) 0.06
0.0994 0.0949 1.09 (0.94–1.27) 0.27
0.0902 0.0949 0.99 (0.85–1.16) 0.91
0.0705 0.0949 0.76 (0.59–0.97) 0.03
0.0803 0.0849 0.87 (0.60–1.27) 0.47
0.0977 0.0915 1.09 (0.93–1.28) 0.28
0.1050 0.0997 1.09 (0.85–1.41) 0.49
0.0954 0.0922 1.09 (0.97–1.23) 0.14
0.0952 0.0966 0.89 (0.71–1.13) 0.34
0.0942 0.0949 0.99 (0.95–1.04) 0.68
0.0950 0.0940 1.05 (0.90–1.23) 0.52
0.0907 0.0979 0.85 (0.60–1.20) 0.36
0.0915 0.0927 1.02 (0.92–1.13) 0.68
0.0916 0.0951 0.99 (0.93–1.06) 0.81
0.0943 0.0949 0.91 (0.71–1.17) 0.46
0.0810 0.0951 0.90 (0.68–1.21) 0.49
0.0916 0.0949 0.99 (0.70–1.40) 0.95
0.0904 0.0930 0.98 (0.94–1.01) 0.19
0.0940 0.0932 1.04 (0.96–1.13) 0.36
0.0885 0.0947 0.97 (0.85–1.10) 0.62
0.0942 0.0954 0.96 (0.84–1.10) 0.59
0.0933 0.0949 0.96 (0.85–1.09) 0.52
0.0980 0.0932 1.07 (0.95–1.22) 0.28
0.0908 0.0948 0.99 (0.81–1.20) 0.90
0.0853 0.0925 0.91 (0.75–1.11) 0.35
0.0935 0.0919 1.04 (0.97–1.12) 0.27
0.1005 0.0921 1.06 (0.94–1.19) 0.35
0.0924 0.0934 0.99 (0.95–1.04) 0.73
0.0896 0.0924 0.95 (0.85–1.05) 0.30
0.0960 0.0926 1.05 (0.90–1.23) 0.52
0.0934 0.0933 0.98 (0.91–1.07) 0.70
0.0904 0.0943 0.98 (0.93–1.03) 0.36
393A. Hollestelle et al. / Gynecologic Oncology 141 (2016) 386–401deleterious BRCA1 or BRCA2 mutations primarily identified through
clinical genetics centers. For the purpose of the current analyses, only
participants of European ancestrywere included. Following genotyping,
quality control exclusions (described below), and analysis-specific ex-
clusions, data from the following women were available for analysis:
46,173 OCAC participants (15,357 patients with invasive epithelial
ovarian cancer and 30,816 controls), 71,170 BCAC participants (33,530
patients with invasive breast cancer and 37,640 controls), and 22,669
CIMBA participants (for ovarian cancer analyses: 2332 affected and
12,433 unaffected BRCA1 carriers, 599 affected and 7305 unaffected
BRCA2 carriers; for breast cancer analyses: 7543 affected and 7222
unaffected BRCA1 carriers, 4138 affected and 3766 unaffected BRCA2
carriers). For OCAC, overall and progression-free survival data were
available for 3096 patients from 13 studies. Overall survival data were
available for 28,471 patients from 26 BCAC studies and for 2623
mutation carriers with breast cancer from 11 CIMBA studies (excluding
studies with less than ten deaths) as described previously [26,27]. Each
study was approved by its relevant governing research ethics commit-
tee, and all study participants provided written informed consent.Table 2
Associations between KRAS rs61764370 and outcome in ovarian and breast cancer.
Ovarian cancer analyses usedOCAC data adjusted for age at diagnosis (overall survival on-
ly), the five European principal components, histology (serous, mucinous, endometrioid,
clear cell, and other epithelial), grade (low versus high), FIGO stage (I–IV), residual disease
after debulking surgery (nil versus any), and stratified by study; breast cancer analyses
usedBCACdata adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hor-
monal and/or chemotherapy and was stratified by study; analyses for BRCA1 and BRCA2
mutation carriers used CIMBA data adjusted for age at diagnosis, tumor size, nodal status,
grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy
and was stratified by study; 95% CI, 95% confidence interval.
No. of
patients
No. of
events
Hazard ratio
(95% CI)
p-Value
Ovarian cancer
Overall survival
All patients 3096 1421 0.94 (0.83–1.07) 0.38
Patients who were suboptimally
debulked after cytoreductive
surgery
1114 784 0.94 (0.78–1.13) 0.50
Post-menopausal patients N 52
years
2226 1276 0.97 (0.84–1.12) 0.70
Progression-free survival
All patients 3096 2144 1.01 (0.90–1.13) 0.84
Patients who were suboptimally
debulked after cytoreductive
surgery
1114 961 1.03 (0.87–1.21) 0.74
Post-menopausal patients N52
years
2226 1603 1.02 (0.90–1.16) 0.76
Breast cancer
Overall survival
All patients 28,471 3013 0.96 (0.87–1.06) 0.38
ER-positive patients 20,071 1754 0.96 (0.85–1.10) 0.58
ER-negative patients 4778 771 0.97 (0.81–1.18) 0.78
Breast cancer-specific survival
All patients 28,471 1693 0.95 (0.83–1.08) 0.40
Overall survival
BRCA1mutation carriers 1706 241 0.72 (0.48–1.08) 0.11
BRCA2mutation carriers 917 162 0.98 (0.65–1.46) 0.902.2. Genotyping and imputation
Genotyping for rs61764370 was performed using the custom iCOGS
Illumina Infinium iSelect BeadChip, as previously described [22–25]. In
total, DNA from 185,443 women of varying ethnic background was ge-
notyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558
CIMBA participants), along with HapMap2 DNAs for European, African,
and Asian populations. Genotype data were also available for three
OCAC genome-wide association studies (UK GWAS, US GWAS, Mayo
GWAS) that had been genotyped using either the Illumina
Human610-Quad Beadchip (12,607 participants) [28] or the Illumina
HumanOmni2.5-8 Beadchip (883 participants). Raw intensity data
files underwent centralized genotype calling and quality control
[22–25]. HapMap2 samples were used to identify women with predict-
ed European intercontinental ancestry; among these women, a set of
over 37,000 unlinked markers was used to perform principal compo-
nent (PC) analysis [29]. The first five and seven European PCs were
found to control adequately for residual population stratification in
OCAC and BCAC data, respectively. Samples with low conversion rate,
extreme heterozygosity, non-female sex, or one of a first-degree relative
pair (the latter for OCAC and BCAC only) were excluded. Variants were
excluded if they were monomorphic or had a call rate b95% (minor al-
lele frequency (MAF) N0.05) or b99% (MAF b0.05), deviation from
Hardy–Weinberg equilibrium (p b 10−7), or N2% duplicate discordance.
In addition to rs61764370, 54 variants within 100 kb on either side
of KRAS on chromosome 12 (25,258,179 to 25,503,854 bp in
GRCh37.p12) were genotyped. Moreover, to provide a common set of
variants across the region for analysis in all the data sets, we also used
imputation to infer genotypes for another 1056 variants and for variants
that failed genotyping. We performed imputation separately for OCAC
samples, BCAC samples, BRCA1mutation carriers, BRCA2mutation car-
riers, and for each of the OCAC GWAS. We imputed variants from the
1000 Genomes Project data using the v3 April 2012 release as the refer-
ence panel [30]. To improve computation efficiency we initially used a
two-step procedure, which involved pre-phasing using the SHAPEIT
software [31] in the first step and imputation of the phased data in the
second.We used the IMPUTE version 2 software [32] for the imputation
for all studies with the exception of the USGWAS for whichwe used the
MACH algorithm implemented in the minimac software version
2012.8.15 andMACHversion 1.0.18 [33].We excluded variants from as-
sociation analyses if their imputation accuracy was r2 b 0.30 or their
MAF was b0.005, resulting in 974 variants genotyped and imputed for
OCAC, 989 variants genotyped and imputed for BCAC, and 1001 variants
genotyped and imputed for CIMBA, including rs61764370 (Supplemen-
tary Tables S5, S6, and S7).2.3. Analysis
Genotypeswere coded for genotype dosage as 0, 1, or 2, based on the
number of copies of the minor allele. For ovarian cancer case–control
analysis (i.e., OCAC studies), logistic regression provided estimated
risks of invasive epithelial ovarian cancer with odds ratios (ORs) and
95% confidence intervals (CIs) adjusting for study, age, and the five
European PCs. Subgroup analyses were conducted by histology, family
ovarian and breast cancer history, menopausal status, time between
ovarian cancer diagnosis and recruitment, and history of multiple
primary cancers. For breast cancer case–control analysis (i.e., BCAC
studies), the association between genotype and invasive breast cancer
risk was evaluated by logistic regression, adjusting for study, age, and
the seven European PCs, providing ORs and 95% CIs. Additional
subgroup analyses were based on receptor status, first-degree family
ovarian and breast cancer history, BRCA1 and BRCA2 mutation status,
enrollment within two years of diagnosis, menopausal status (i.e. last
menstruation longer than twelve months ago), age at diagnosis less
than 52 years, and history of hormone replacement therapy use (i.e. lon-
ger than twelve months use). Risk analysis for BRCA1 and BRCA2muta-
tion carriers (i.e. CIMBA studies) was done using a Cox proportional
hazard model to estimate hazard ratios (HRs) per copy of the minor al-
lele, with age as follow-up time and stratified by country of residence;
US and Canadian strata were further subdivided by self-reported
Ashkenazi Jewish ancestry [24,25]. Aweighted cohort approachwas ap-
plied to correct for potential testing bias due to overrepresentation of
cases in the study population [34]. We used robust variance estimation
to allow for the non-independence of carriers within the same family
[35]. To assess associations with ovarian cancer risk, mutation carriers
were followed from birth until ovarian cancer diagnosis (event), a
risk-reducing salpingo-oophorectomy (RRSO) or the age at enrollment,
Fig. 1. Regional association plots for variants within the genomic region 100 kb either side of KRAS and risk of ovarian and breast cancer. X-axis position is referent to position (bp) on
chromosome 12, build GRCh37.p12; yellow line indicates position of KRAS; red triangle indicates rs61764370. Y-axis is−log10(p-values) from association tests for risk of A) ER-negative
breast cancer, B) ER-positive breast cancer, C) breast cancer in BRCA1mutation carriers, D) breast cancer in BRCA2mutation carriers, E) epithelial ovarian cancer, F) epithelial ovarian can-
cer in BRCA1mutation carriers, and G) epithelial ovarian cancer in BRCA2mutation carriers.
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Fig. 2. Power curve for modest risk variants according to the total sample size. X-axis is
total sample size for which case–control ratio is 1:1. Y-axis is the statistical power
(range 0 · 5–1 · 0) for variants given a range of risks, assuming alpha = 0 · 01 and
minor allele frequency 0 · 09.
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women diagnosed or censored within two years before their enroll-
ment. To assess associations with breast cancer risk, mutation carriers
were followed from birth until a breast cancer diagnosis (i.e. either duc-
tal carcinoma in situ or invasive breast cancer), ovarian cancer diagno-
sis, a risk-reducing bilateral prophylactic mastectomy or the age at
enrollment, whichever occurred first.
Survival analysis of OCAC patients used Cox proportional hazards
models estimating HRs and 95% CIs considering overall survival as
well as progression-free survival following ovarian cancer diagnosis.
Overall survival was adjusted for age at diagnosis, the five European
PCs, histology, grade, FIGO stage, and residual disease after debulking
surgery, and stratified by study, left truncating at the date of study
entry and right censoring at five years to minimize events due to
other causes. Progression-free survival was analyzed as for overall
survival, but without adjustment for age and right censoring, and was
defined as the time between the date of histologic diagnosis and the
first confirmed sign of disease recurrence or progression, based on
GCIG (Gynecological Cancer InterGroup) criteria [36].We also performed
subgroup analysis of patients suboptimally debulked after cytoreductive
surgery (residual disease N1 cm) and of post-menopausal patients (age
at diagnosis N52 years). Survival analysis of BCAC patients used Cox pro-
portional hazard models estimating HRs and 95% CIs considering overall
and breast cancer-specific survival following breast cancer diagnosis.
Models were adjusted for age at diagnosis, tumor size, nodal status,
grade, adjuvant hormonal and/or chemotherapy, and stratified by
study, left-truncating at the date of study entry and right censoring at
ten years. In addition, we performed subgroup analysis on ER-positive
and ER-negative patients. For CIMBA breast cancer patients associations
between genotype and overall survival were evaluated using Cox
proportional hazard models estimating HRs and 95% CIs. Models were
adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant
hormonal and/or chemotherapy, and preventive bilateral oophorectomy
and stratified by study, left-truncating at the date of study entry and right
censoring at twenty years. Analyses were performed using STATA ver-
sion 12.0 (StataCorp, Texas, USA).
3. Results
The results of the overall analysis as well as the subgroup analyses
investigating the association between the minor allele at rs61764370
and ovarian cancer risk, breast cancer risk, and ovarian and breast
cancer risks in BRCA1 and BRCA2 mutation carriers are shown in
Table 1. Associations with clinical outcomes in and ovarian and breast
cancer patients including BRCA1 and BRCA2 mutation carriers are
shown in Table 2 and Supplementary Table S4.
We found no evidence for association between the rs61764370 G al-
lele and ovarian or breast cancer risk. The most statistically significant
association was observed for risk of low-grade serous ovarian cancer
(n = 485; OR 0.76, 95% CI 0.59–0.97, p = 0.031), but this finding was
not significant after Bonferroni correction for multiple testing. We also
evaluated the association for additional specific subgroups in which an
association with rs61764370 had been reported previously [3–6]. Ovar-
ian cancer subgroups considered BRCA1 mutation carriers as well as
BRCA1 and BRCA2 screened-negative patients with first degree family
histories of breast or ovarian cancer and patients who had been diag-
nosed with breast cancer before their ovarian cancer diagnoses. For
breast cancer these included, among others, BRCA1 mutation carriers,
patients diagnosed with ER- and PR-negative tumors, and patients
diagnosed with triple negative tumors before age 52 years. Importantly,
we observed no evidence for association of rs61764370 with any of
these subgroups (detailed in Table 1), with all ORs close to unity and
very narrow CIs including unity.
Similarly, case-only analyses did not reveal any associations
between rs61764370 genotype and ovarian and breast cancer clinical
features or outcome (Table 2 and Supplementary Table S4). Forexample, the previously reported association between rs61764370
and risk of ERBB2-positive and high grade breast cancer in hormone re-
placement therapy users [18] was not replicated (Supplementary
Table S4), and in ovarian cancer analyses we found no evidence of re-
duced survival among patients diagnosed after age 52 years or patients
with suboptimal debulking after cytoreductive surgery (Table 2) [14].
The G allele of rs61764370 was also not associated with survival of
breast cancer patients (Table 2).
Finally, we evaluated the association between the primary pheno-
types of interest and common genetic variation (MAF N 0.02) in the ge-
nomic region of KRAS (i.e., within 100 kb on either side of the gene),
using imputed and genotyped data on 974 variants for OCAC, 989 vari-
ants for BCAC, and 1001 variants genotyped and imputed for CIMBA
(Supplementary Tables S5, S6, and S7). We found no evidence of associ-
ation for any of these variants, including rs61764370 and rs17388148,
with these phenotypes that would withstand Bonferroni correction for
multiple testing, as detailed in Supplementary Tables S5, S6, and S7
and shown in regional association plots (Fig. 1).
4. Discussion
Our analysis of 140,012 women genotyped for inherited variants in
the KRAS region provides definitive clarification of the role of these var-
iants in ovarian and breast cancer susceptibility and outcome. We have
found no evidence to support an association between rs61764370 and
ovarian or breast cancer risk, or clinical outcomes in patients with ovar-
ian or breast cancer. In the absence of any association and with ORs
close to unity we would not typically consider sub-group analyses, par-
ticularly sub-groups forwhich differential associationswould not be ex-
pected to occur. However, given the previous positive associations
reported for a myriad of different subgroups, we tested for association
among each of these subgroups and found no evidence to support the
previously reported associations.
Our study has notable strengths. The vast majority (i.e. N95%) of the
samples were genotyped using the same genotyping platform and
employing a common approach to genotype calling and quality control;
additional samples used denser arrays and nearly identical procedures.
The very large sample sizes for all themajor phenotypes of interest pro-
vide substantial statistical power to exclude any clinically relevant asso-
ciated risks for themajor phenotypes of interest (Fig. 2). The null results
found here are thus not due to lack of statistical power, and this analysis
also had greater than 80% power to detect association for most of the
subgroups, although for some subgroups it was not possible to exclude
396 A. Hollestelle et al. / Gynecologic Oncology 141 (2016) 386–401modest risks. In contrast to the current findings, other genetic associa-
tion analyses using the same genotyping platform and the same studies
as included here have identified more than 90 common germline
variants associated with ovarian or breast cancer risk at p b 5 × 10−8
[22,23,37]. While critiques on a previous null KRAS report have sug-
gested that inclusion of male controls, use of “prevalent” cases, and reli-
ance on a surrogate genetic variant may have led to falsely negative
conclusions, these are not issues in the present data set. Rather, we
demonstrate the importance of international collaboration to identify
true associations aswell as to refute false associations, an equally impor-
tant objective.
The rise of individualized medicine including the use of panels of
common variants to predict cancer riskmore accurately than using fam-
ily history alone holds great promise [38]. For example, the 31 prostate
cancer susceptibility alleles confirmed as of 2011 (at p b 5 × 10−8) can
be combined to identify men in the top one percent of the risk distribu-
tion having a 3.2-fold increased risk [39]. Prediction has since then im-
proved with now over 70 prostate cancer susceptibility alleles [40]
and the utility of these genetic tests is currently under clinical evalua-
tion. A similar clinical examination in ovarian and breast cancer is not
far behind, with now over 18 and 77 confirmed susceptibility alleles, re-
spectively, for these cancers [22,23]. The genotype at rs61764370, how-
ever, does not predict ovarian or breast cancer risk, even among
particular subgroups of women or for particular subtypes of disease,
nor is it a marker of differential outcome following diagnosis with
these cancers. Therefore, genetic test results for rs61764370 should
not be used to counsel women about their ovarian or breast cancer
risks or outcome.Our results highlight the dangers of developing clinical
tests without appropriate data from carefully conducted, large-scale
studies to establish clinical validity.
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